Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
Key facts
- Who runs it
- Sanofi
- Where
- Belgium, France, Germany, Poland, Portugal, and Spain61 sites in 6 countriesChoose a country to see its sites
- Trial code
- NCT07890454
- EU 2026-526221-18-00
- U1111-1332-8880
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 6,000 people, planned
- Started
- 28 Oct 2026
- Expected to end
- 28 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- IIV-HD (standalone)
- NVXC19 (EU licensed, standalone)
- IIV-HD + NVXC19 combination
- Placebo, normal saline
- Record updated
- 13 November 2026
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Aged 60 years or older on the day of inclusion
- Informed consent form has been signed and dated
- Able to attend all scheduled visits and to comply with all study procedures
- Participant must be able to receive an injection in the deltoid muscle of both arms
- Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine Inclusion criteria to be checked at Visit 1 (D01)
- Aged 60 years or older on the day of inclusion
- Participants who are healthy or with pre-existing stable condition, as determined by medical evaluation including medical history and physical examination
- Non-childbearing potential (i.e., post-menopausal for at least 1 year or surgically sterile)
- lnformed consent form has been signed and dated
- Able to attend all scheduled visits and to comply with all study procedures
- Participant must be able to receive an injection in the deltoid muscle of both arms
- Participant must have completed a primary vaccination series against SARS-CoV-2 and at least 1 booster with a locally authorized or approved COVID-19 vaccine
Who cannot take part
- Known/suspected immunodeficiency; immunosuppressive therapy in past 6 months; long-term systemic corticosteroids
- Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion
- Prior history of myocarditis, pericarditis, or myopericarditis Prior/concomitant therapy
- Any vaccine given within 4 weeks before or within 4 weeks after study intervention
- Previous vaccination against influenza (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of influenza infection in the previous 6 months
- Previous vaccination against COVID-19 (in the previous 6 months before study intervention) with an investigational or marketed vaccine OR history of COVID-19 infection in the previous 6 months
- Has received a blood transfusion or blood-derived products, including immunoglobulins, in the past 3 months Other exclusion
- Known systemic hypersensitivity to any study intervention components or history of life-threatening reaction to study interventions or products with the same substances
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular injection, based on investigator's judgment
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
- Moderate/severe acute illness/infection (per investigator judgment)/fever (≥38.0°C [≥100.4°F]) on study intervention day. Include participant only after the condition or fever has resolved
- History of serious adverse reaction to any influenza or COVID-19 vaccines per investigator's judgment
- Personal or family history of Guillain-Barré syndrome
- Self-reported thrombocytopenia, contraindicating intramuscular injection, based on investigator's judgment
- Deprived of freedom by an administrative or court order, or being in an emergency setting, or hospitalized involuntarily
- Is an investigator, investigator/study center employee, or immediate family member (parent, spouse, natural/adopted child) of the investigator/employee with direct involvement in the study The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60 years of age and older. Placebo will be coadministered in the IIV-HD + NVXC19 study group to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive 2 injections at enrollment, one in each deltoid muscle.
Read full original descriptionShow less
Study details include:
* The study duration will be approximately 12 months per participant * Study intervention will be administered via a single IM injection into the right and left deltoid muscles on day (D)01
The 2 groups in the trial
- Group 1, IIV-HD and EU-licensed NVXC19Existing treatment, for comparison
IIV-HD and NVXC19 co-administered in opposite deltoid muscles
Treatment: IIV-HD (standalone) and NVXC19 (EU licensed, standalone)
- Group 2, IIV-HD + NVXC19 combination and placeboTreatment being tested
IIV-HD + NVXC19 and Placebo co-administered in opposite deltoid muscles
Treatment: IIV-HD + NVXC19 combination and Placebo, normal saline
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Parallel, Randomized, Modified Double-Blind, Active-Controlled, Multi-Arm Study to Assess the Safety and Immunogenicity of a Combination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
- Record updated
- 13 November 2026